VANCOUVER, Washington, April 29, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), CytoDyn, a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that management will present a company overview at the ThinkEquity investor conference on Thursday, May 2, 2019 at 3:30 p.m. Eastern time (12:30 p.m. Pacific time) in the Lotus East room of The Mandarin Oriental Hotel in New York City. Dr. Nader Pourhassan, President and CEO of CytoDyn, and Dr. Richard Pestell, Chief Medical Officer of CytoDyn, will present an overview of the company’s various clinical programs and meet individually with investors throughout the conference.
A live webcast and replay of the presentation from the ThinkEquity conference will be available on the Investors section of the Company’s website, http://ir.cytodyn.com/. The replay of the webcast will be available approximately one hour after the webcast presentation ends and will be accessible for 90 days. The live webcast can also be accessed at: http://wsw.com/webcast/thinkequity/cydy.ob/. Web participants are encouraged to go to either website 15 minutes prior to the start of the presentation to register, download and install any necessary software.
Investors and other conference attendees interested in meeting with Dr. Pourhassan and Dr. Pestell should contact: Marek Ciszewski, J.D. at mciszewski@edisongroup.com.
CONTACTS
Investors:
Nader Pourhassan, Ph.D.
President & CEO
npourhassan@cytodyn.com
Marek Ciszewski, J.D.
Edison, Inc.
MCiszewski@EdisonGroup.com